

FIG. 7. C2C12 myotubes were transfected with the control nonsilencing siRNA and siRNA against FHC, MnSOD, and iNOS using the transfection reagent. The cells were used for experiments 48 h after siRNA transfection and incubated with or without recombinant adiponectin at 12 h before the experiments. ROS generations and FHC, MnSOD, and iNOS mRNA in each of the cells were determined. Each column shows the mean \pm SE obtained from four samples in the presence or absence of adiponectin. *Significant difference ($P < 0.05$) relative to the paired control cells in the absence of adiponectin. **Significant difference ($P < 0.01$) relative to control siRNA-transfected cells in the presence of adiponectin. N.S., not significant relative to paired control cells in the absence of adiponectin.

required for iron sequestration (16). On the other hand, FLC has no ferroxidase activity but is likely to contribute to stabilization of assembled ferritin proteins for long-term

iron storage (33). AP-1 motifs or NF- κ B-responsive elements have been found in the promoter region of FHC (22,34) but not in that of FLC. Indeed, our results revealed only the expression of FHC (i.e., not that of FLC) to be increased in response to adiponectin exposure. In addition to this iron-mediated regulation, ferritin is regulated by immune/inflammatory cytokines. For example, similar changes in FHC-to-FLC ratios (i.e., increased FHC with no significant change in FLC expression) were observed in myoblasts following cytokine stimulation (35). Serum levels of ferritin were previously reported to be increased in patients with nonalcoholic steatohepatitis (36) or type 2 diabetes with obesity (37), disorders characterized by inflammation in the liver or adipose tissues. In these conditions, NF- κ B plays a pivotal role in cytokine-induced FHC upregulation (17).

In recent decades, studies of NF- κ B have concentrated mainly on discovering the molecules and biochemical processes essential to the signaling cascades controlling NF- κ B activity, since NF- κ B is known to be one of the critical transcription factors mediating inflammatory cellular responses, such as the production of cytokines and adhesion molecules (36,38). However, recent studies have focused on elucidating the novel mechanism whereby NF- κ B exerts a protective effect against cytotoxicity. Notably, Pham et al. (17) discovered how NF- κ B antagonizes TNF- α -induced apoptosis. They identified FHC as a critical mediator of NF- κ B protective activity against TNF- α -induced cytotoxicity and concluded that FHC mediates suppression of ROS accumulation, which in turn prevents persistent activation of the Jun NH₂-terminal kinase pathway, thereby inhibiting apoptosis. Thus, in adiponectin-sensitive tissues, such as skeletal muscle cells, FHC upregulation induced by adiponectin plays a pivotal role in the antagonistic cross-talk between the NF- κ B and ROS/Jun NH₂-terminal kinase pathways.

The physiological roles of NF- κ B in skeletal muscles are currently unknown despite the well-recognized increase in NF- κ B activity with acute exercise and muscle contraction (39). However, given the array of NF- κ B target gene products in skeletal muscles, NF- κ B is speculated to




FIG. 8. Effects of adiponectin overexpression on FHC regulation in skeletal muscles. Mice were systemically injected with recombinant adenovirus expressing LacZ (L group) or adiponectin (A group) via the tail vein. Three days after virus infection, we confirmed increased serum adiponectin levels, using a mouse/rat adiponectin enzyme-linked immunosorbent assay kit (B) and by immunoblot analysis (C) and quantitatively analyzed FHC expression in total hindlimbs (A), as previously described (19). Representative data of three mice (A) or one mouse (C) from each group are presented. Each column shows the means \pm SE obtained from seven animals in each group. *Significant difference ($P < 0.05$) relative to L group.

serve as a scavenger in states of oxidative stress because stress factors accumulate with exercise and muscle contraction (40). Along with FHC, MnSOD and iNOS were demonstrated to be increased and to be targets of the NF- κ B gene product. Thus, our results suggest adiponectin to support NF- κ B activation and thereby produce beneficial effects in skeletal muscle by reducing ROS via FHC upregulation.

In conclusion, we have clarified that NF- κ B-targeted genes were upregulated by adiponectin in skeletal muscle cells, making this report, to our knowledge, the first ever demonstration of this property of adiponectin. Taking into consideration that ROS activity is subject to negative feedback regulation by NF- κ B, adiponectin plays key roles in reducing oxidative stress and in cytoprotection against ROS in skeletal muscles. In fact, previous studies (41,42) have demonstrated a close relation between oxidative stress and insulin resistance. Thus, ROS production, following the accumulation of excessive fat, may account for the link between obesity and insulin resistance. Considering the beneficial effects of adiponectin on obesity-linked insulin resistance, FHC upregulation by adiponectin may play an important role in the mechanism by which adiponectin improves insulin resistance.

ACKNOWLEDGMENTS

This study was supported by Grant-in-Aid for Scientific Research no. 18591001 (to K.I.) from the Ministry of Education, Culture, Sports, Science and Technology of Japan.

No potential conflicts of interest relevant to this article were reported.

We thank Y. Asami for help with some of the experiments and are grateful to S. Ohshima and N. Hiroswawa for their excellent technical assistance with the flow cytometry and the two-dimensional electrophoresis, respectively.

REFERENCES

- Guerre-Millo M: Adipose tissue and adipokines: for better or worse. *Diabetes Metab* 30:13–19, 2004
- Shapiro L, Scherer PE: The crystal structure of a complement-1q family protein suggests an evolutionary link to tumor necrosis factor. *Curr Biol* 8:335–338, 1998
- Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara H, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, Ezaki O, Akanuma Y, Gavrilova O, Vinson C, Reitman ML, Kagechika H, Shudo K, Yoda M, Nakano Y, Tobe K, Nagai R, Kimura S, Tomita M, Froguel P, Kadowaki T: The fat-derived hormone adiponectin reverses insulin resistance associated with both lipotrophy and obesity. *Nat Med* 7:941–946, 2001
- Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K: Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. *Biochem Biophys Res Commun* 221:286–289, 1996
- Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai R, Kahn BB, Kadowaki T: Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. *Nat Med* 8:1288–1295, 2002
- Ouchi N, Kihara S, Arita Y, Nishida M, Matsuyama A, Okamoto Y, Ishigami M, Kuriyama H, Kishida K, Nishizawa H, Hotta K, Muraguchi M, Ohmoto Y, Yamashita S, Funahashi T, Matsuzawa Y: Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. *Circulation* 103:1057–1063, 2001
- Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, Hotta K, Nishida M, Takahashi M, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y: Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. *Circulation* 100:2473–2476, 1999
- Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, Sugiyama T, Miyagishi M, Hara K, Tsunoda M, Murakami K, Ohteki T, Uchida S, Takekawa S, Waki H, Tsuno NH, Shibata Y, Terauchi Y, Froguel P, Tobe K, Koyasu S, Taira K, Kitamura T, Shimizu T, Nagai R, Kadowaki T: Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. *Nature* 423:762–769, 2003
- Waki H, Yamauchi T, Kamon J, Ito Y, Uchida S, Kita S, Hara K, Hada Y, Vasseur F, Froguel P, Kimura S, Nagai R, Kadowaki T: Impaired multimerization of human adiponectin mutants associated with diabetes: molecular structure and multimer formation of adiponectin. *J Biol Chem* 278:40352–40363, 2003
- Tsao TS, Tomas E, Murrey HE, Hug C, Lee DH, Ruderman NB, Heuser JE, Lodish HF: Role of disulfide bonds in Acrp30/adiponectin structure and signaling specificity: different oligomers activate different signal transduction pathways. *J Biol Chem* 278:50810–50817, 2003
- Pajvani UB, Hawkins M, Combs TP, Rajala MW, Doebber T, Berger JP, Wagner JA, Wu M, Knopps A, Xiang AH, Utzschneider KM, Kahn SE, Olefsky JM, Buchanan TA, Scherer PE: Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. *J Biol Chem* 279:12152–12162, 2004
- Kobayashi H, Ouchi N, Kihara S, Walsh K, Kumada M, Abe Y, Funahashi T, Matsuzawa Y: Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. *Circ Res* 94:27–31, 2004
- Lara-Castro C, Luo N, Wallace P, Klein RL, Garvey WT: Adiponectin multimeric complexes and the metabolic syndrome trait cluster. *Diabetes* 55:249–259, 2006
- Nakashima R, Kamei N, Yamane K, Nakanishi S, Nakashima A, Kohno N: Decreased total and high molecular weight adiponectin are independent risk factors for the development of type 2 diabetes in Japanese-Americans. *J Clin Endocrinol Metab* 91:3873–3877, 2006
- Arosio P, Levi S: Ferritin, iron homeostasis, and oxidative damage. *Free Radic Biol Med* 33:457–463, 2002
- Torti FM, Torti SV: Regulation of ferritin genes and protein. *Blood* 99:3505–3516, 2002
- Pham CG, Bubicic C, Zazzeroni F, Papa S, Jones J, Alvarez K, Jayawardena S, De Smaele E, Cong R, Beaumont C, Torti FM, Torti SV, Franzoso G: Ferritin heavy chain upregulation by NF- κ B inhibits TNF α -induced apoptosis by suppressing reactive oxygen species. *Cell* 119:529–542, 2004
- Sinha S, Perdomo G, Brown NF, O'Doherty RM: Fatty acid-induced insulin resistance in L6 myotubes is prevented by inhibition of activation and nuclear localization of nuclear factor kappa B. *J Biol Chem* 279:41294–41301, 2004
- Inukai K, Shewan AM, Pascoe WS, Katayama S, James DE, Oka Y: Carboxy terminus of glucose transporter 3 contains an apical membrane targeting domain. *Mol Endocrinol* 18:339–349, 2004
- Miyake S, Makimura M, Kanegae Y, Harada S, Sato Y, Takamori K, Tokuda C, Saito I: Efficient generation of recombinant adenoviruses using adenovirus DNA-terminal protein complex and a cosmid bearing the full-length virus genome. *Proc Natl Acad Sci U S A* 93:1320–1324, 1996
- Inukai K, Nakashima Y, Watanabe M, Takata N, Sawa T, Kurihara S, Awata T, Katayama S: Regulation of adiponectin receptor gene expression in diabetic mice. *Am J Physiol Endocrinol Metab* 288:E876–E882, 2005
- Kwak EL, Larochelle DA, Beaumont C, Torti SV, Torti FM: Role for NF- κ B in the regulation of ferritin H by tumor necrosis factor- α . *J Biol Chem* 270:15285–15293, 1995
- Bevilacqua MA, Faniello MC, Quaresima B, Tianio MT, Giuliano P, Feliciello A, Avvedimento VE, Cimino F, Costanzo F: A common mechanism underlying the E1A repression and the cAMP stimulation of the H ferritin transcription. *J Biol Chem* 272:20736–20741, 1997
- Hattori Y, Hattori S, Kasai K: Globular adiponectin activates nuclear factor-kappa B in vascular endothelial cells, which in turn induces expression of proinflammatory and adhesion molecule genes. *Diabetes Care* 29:139–141, 2006
- McConnell GK, Bradley SJ, Stephens TJ, Canny BJ, Kingwell BA, Lee-Young RS: Skeletal muscle nNOS μ protein content is increased by exercise training in humans. *Am J Physiol Regul Integr Comp Physiol* 293:R831–R838, 2007
- Yoon MJ, Lee GY, Chung JJ, Ahn YH, Hong SH, Kim JB: Adiponectin increased fatty acid oxidation in skeletal muscle cells by sequential activation of AMP-activated protein kinase, p38 mitogen-activated protein kinase, and peroxisome proliferator-activated receptor α . *Diabetes* 55:2562–2570, 2006
- Barnes PJ, Karin M: Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. *N Engl J Med* 336:1066–1071, 1997
- Makarov SS: NF- κ B as a therapeutic target in chronic inflammation: recent advances. *Mol Med Today* 6:441–448, 2000
- Hayden MS, West AP, Ghosh S: NF- κ B and the immune response. *Oncogene* 25:6758–6780, 2006

30. Orino K, Lehman L, Tsuji Y, Ayaki H, Torti SV, Torti FM: Ferritin and the response to oxidative stress. *Biochem J* 357:241–247, 2001
31. Bevilacqua MA, Faniello MC, Russo T, Cimino F, Costanzo F: Transcriptional regulation of the human H ferritin-encoding gene (FERH) in G418-treated cells: role of the B-box-binding factor. *Gene* 141:287–291, 1994
32. Cozzi A, Corsi B, Levi S, Santambrogio P, Albertini A, Arosio P: Overexpression of wild type and mutated human ferritin H-chain in HeLa cells: in vivo role of ferritin ferroxidase activity. *J Biol Chem* 275:25122–25129, 2000
33. Levi S, Luzzago A, Cesareni G, Cozze A, Franceschinelli F, Albertini A, Arosio P: Mechanism of ferritin iron uptake: activity of the H-chain and deletion mapping of the ferro-oxidase site: a study of iron uptake and ferro-oxidase activity of human liver, recombinant H-chain ferritins, and of two H-chain deletion mutants. *J Biol Chem* 263:18086–18092, 1988
34. Tsuji Y, Akebi N, Lam TK, Nakabeppu Y, Torti SV, Torti FM: FER-1, an enhancer of the ferritin H gene and a target of E1A-mediated transcriptional repression. *Mol Cell Biol* 15:5152–5164, 1995
35. Miller LL, Miller SC, Torti SV, Tsuji Y, Torti FM: Iron independent induction of ferritin H-chain by tumor necrosis factor. *Proc Natl Acad Sci U S A* 88:4946–4950, 1991
36. Fargion S, Mattioli M, Fracanzani AL, Sampietro M, Tavazzi D, Fociani P, Taioli E, Valenti L, Fiorelli G: Hyperferritinemia, iron overload, and multiple metabolic alterations identify patients at risk for nonalcoholic steatohepatitis. *Am J Gastroenterol* 96:2448–2455, 2001
37. Forouhi NG, Harding AH, Allison M, Sandhu MS, Welch A, Luben R, Bingham S, Khaw KT, Wareham NJ: Elevated serum ferritin levels predict new-onset type 2 diabetes: results from the EPIC-Norfolk prospective study. *Diabetologia* 50:949–956, 2007
38. Kim I, Moon SO, Kim SH, Kim HJ, Koh YS, Koh GY: Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-kappa B activation in endothelial cells. *J Biol Chem* 276:7614–7620, 2001
39. Lappas M, Permezel M, Georgiou HM, Rice GE: Nuclear factor kappa B regulation of pro-inflammatory cytokines in human gestational tissues in vitro. *Biol Reprod* 67:668–673, 2002
40. Ho RC, Hirshman MF, Li Y, Cai D, Farmer JR, Aschenbach WG, Witczak CA, Shoelson SE, Goodyear LJ: Regulation of I- κ B kinase and NF- κ B in contracting adult rat skeletal muscle. *Am J Physiol Cell Physiol* 289:C794–C801, 2005
41. Rudich A, Tirosch A, Potashnik R, Hemi R, Kanety H, Bashan N: Prolonged oxidative stress impairs insulin-induced GLUT4 translocation in 3T3-L1 adipocytes. *Diabetes* 47:1562–1569, 1998
42. Houstis N, Rosen ED, Lander ES: Reactive oxygen species have a causal role in multiple forms of insulin resistance. *Nature* 440:944–948, 2006

DOC2B: A Novel Syntaxin-4 Binding Protein Mediating Insulin-Regulated GLUT4 Vesicle Fusion in Adipocytes

Naofumi Fukuda,¹ Masahiro Emoto,¹ Yoshitaka Nakamori,¹ Akihiko Taguchi,¹ Sachiko Miyamoto,¹ Shinsuke Uraki,¹ Yoshitomo Oka,² and Yukio Tanizawa¹

OBJECTIVE—Insulin stimulates glucose uptake in skeletal muscle and adipose tissues primarily by stimulating the translocation of vesicles containing a facilitative glucose transporter, GLUT4, from intracellular compartments to the plasma membrane. The formation of stable soluble *N*-ethyl-maleimide-sensitive fusion protein [NSF] attachment protein receptor (SNARE) complexes between vesicle-associated membrane protein-2 (VAMP-2) and syntaxin-4 initiates GLUT4 vesicle docking and fusion processes. Additional factors such as munc18c and tomosyn were reported to be negative regulators of the SNARE complex assembly involved in GLUT4 vesicle fusion. However, despite numerous investigations, the positive regulators have not been adequately clarified.

RESEARCH DESIGN AND METHODS—We determined the intracellular localization of DOC2b by confocal immunofluorescent microscopy in 3T3-L1 adipocytes. Interaction between DOC2b and syntaxin-4 was assessed by the yeast two-hybrid screening system, immunoprecipitation, and *in vitro* glutathione *S*-transferase (GST) pull-down experiments. Cell surface externalization of GLUT4 and glucose uptake were measured in the cells expressing DOC2b constructs or silencing DOC2b.

RESULTS—Herein, we show that DOC2b, a SNARE-related protein containing double C2 domains but lacking a transmembrane region, is translocated to the plasma membrane upon insulin stimulation and directly associates with syntaxin-4 in an intracellular Ca²⁺-dependent manner. Furthermore, this process is essential for triggering GLUT4 vesicle fusion. Expression of DOC2b in cultured adipocytes enhanced, while expression of the Ca²⁺-interacting domain mutant DCO2b or knockdown of DOC2b inhibited, insulin-stimulated glucose uptake.

CONCLUSIONS—These findings indicate that DOC2b is a positive SNARE regulator for GLUT4 vesicle fusion and mediates insulin-stimulated glucose transport in adipocytes. *Diabetes* 58: 377–384, 2009

Insulin stimulates glucose uptake in skeletal muscles and adipose tissues primarily by stimulating the translocation of vesicles containing a facilitative glucose transporter, GLUT4, from intracellular compartments to the plasma membrane (1,2). In addition to this translocation step, membrane fusion processes are also controlled by insulin (3,4). Like other regulated exocytotic processes in many cell types, the formation of stable soluble *N*-ethyl-maleimide-sensitive fusion protein [NSF] attachment protein receptor (SNARE) complexes between vesicle-associated membrane protein-2 (VAMP-2) and syntaxin-4 initiates GLUT4 vesicle docking and fusion processes (5). However, the precise mechanism by which insulin regulates SNARE complex assembly remains poorly understood.

In neurons, Ca²⁺ triggers exocytotic membrane fusion of synaptic vesicles to the plasma membrane, and calcium sensor proteins such as synaptotagmins have critical roles in this process (6,7). Similar mechanisms result in GLUT4 vesicle fusion in adipocytes and muscle cells. Whitehead et al. (8) demonstrated, and we confirmed, that reduction of intracellular Ca²⁺ ([Ca²⁺]_i) using the membrane-permeable Ca²⁺-chelating agent BAPTA-AM diminished insulin-stimulated glucose transport, whereas this reagent did not inhibit GLUT4 translocation to the plasma membrane (i.e., GLUT4 vesicle trafficking was not impaired) (8) (N.F., M.E., unpublished observation). These observations suggest that an appropriate intracellular Ca²⁺ level may be required for the final docking/fusion steps of GLUT4 vesicles in adipocytes.

The universal role of Ca²⁺ as a trigger for regulated exocytosis predicts the existence of conserved proteins capable of activating the fusion machinery upon binding Ca²⁺. Although many proteins have been suggested to play such a role, synaptotagmins have attracted the most attention as putative calcium sensor proteins functioning in regulated exocytosis (9). Synaptotagmin family proteins have tandem C2 domains at the C-terminus. These two domains, C2A and C2B, are conserved in all 13 synaptotagmins described to date and constitute Ca²⁺-binding modules (10). Many proteins have been identified as being involved in the GLUT4 vesicle fusion machinery in adipocytes. However, neither synaptotagmins nor other calcium sensor proteins have as yet been reported to regulate GLUT4 vesicle fusion.

We investigated, in detail, the mechanisms of Ca²⁺-dependent GLUT4 vesicle fusion in adipocytes. We searched for double C2 domain proteins as candidate Ca²⁺ sensor proteins suitable for the relatively slow (on the order of several minutes) SNARE complex formation, and we found that DOC2b bound syntaxin-4 upon insulin stimulation in an intracellular Ca²⁺-dependent manner and

From the ¹Division of Endocrinology, Metabolism, Hematological Sciences, and Therapeutics, Department of Bio-Signal Analysis, Yamaguchi University Graduate School of Medicine, Ube, Japan; and the ²Division of Molecular Metabolism and Diabetes, Tohoku University Graduate School of Medicine, Sendai, Japan.

Corresponding author: Dr. Masahiro Emoto, emotom@yamaguchi-u.ac.jp.

Received 3 March 2008 and accepted 17 November 2008.

Published ahead of print at <http://diabetes.diabetesjournals.org> on 25 November 2008. DOI: 10.2337/db08-0303.

Additional information for this article can be found in an online appendix at: <http://dx.doi.org/10.2337/db08-0303>.

© 2009 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See <http://creativecommons.org/licenses/by-nc-nd/3.0/> for details.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

mediated GLUT4 vesicle fusion. DOC2b may be a downstream target of the insulin signal and a positive regulator of SNARE assembly involving regulated exocytosis in adipocytes.

RESEARCH DESIGN AND METHODS

Mouse DOC2a and DOC2b cDNA constructs were kindly provided by Dr. R.R. Duncan (University of Edinburgh, Edinburgh, U.K.). Mouse munc18c cDNA construct was kindly provided by Dr. T. Takuma (School of Dentistry, Health Sciences University of Hokkaido, Hokkaido, Japan).

Cell culture. 3T3-L1 fibroblasts were grown in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal bovine serum (FBS) at 37°C. The cells (3–5 days after confluence) differentiated into adipocytes with incubation in the same DMEM, containing 0.5 mmol/l isobutylmethylxanthine, 0.25 μ mol/l dexamethasone, and 4 μ g/ml insulin, for 3 days and were then grown in DMEM with 10% FBS for an additional 5–8 days.

Plasmids and antibodies. Wild-type DOC2b was subcloned into pGFP-C2, pDsRed2-C1 (Clontech, Palo Alto, CA), and pGEX-6P1 (GH Healthcare, Buckinghamshire, U.K.) vectors. Calcium interacting domain mutants (CIMs) of DOC2b (D157N, D163N, D297N, and D303N) were subcloned into pGFP-C2 and pGEX-6P1 vectors. We also constructed syntaxin-4 and a series of deletion mutants of DOC2b corresponding to Δ munc13 interaction domain (MID) (amino acids 36–413), Δ C2A (2–120 and 252–413), and Δ C2B (2–264) in a pGFP-C2 vector. Myc-tagged DOC2b (wild-type or CIM) was subcloned into a pcDNA3 vector. All chemically synthesized and PCR-derived DNA sequences were verified by DNA sequencing.

Rabbit polyclonal DOC2b antibody was generated against the peptide sequence CGARDDDEDVDQL specific for DOC2b isoform. This antibody was found to cross-react minimally (online appendix Fig. S1 [available at <http://dx.doi.org/10.2337/db08-0303>]). The following antibodies were used: monoclonal anti-GLUT4 (clone 1F8) (R&D systems, Minneapolis, MN), polyclonal anti-GLUT4, anti-GST (Santa Cruz Biotechnology, Santa Cruz, CA), anti-myc (clone 9E10) (Covance, Princeton, NJ), polyclonal anti-syntaxin-4 (Synaptic Systems, Gottingen, Germany), and fluorescein-conjugated and horseradish peroxidase-conjugated secondary antibodies (Jackson Immuno Research, West Grove, PA).

DOC2b shRNA construct. Short-hairpin RNA (shRNA) specific for mouse DOC2b was designed to have a 5'-GCCAGATGTAGACAAGAAATC-3' sequence. Synthetic complementary single-stranded DNA of the target sequence was annealed, and the double-stranded DNA was inserted into a pPUR+U6i cassette (11). This shRNA decreased DOC2b protein expression to 10–20% of the control level within 74 h. A same cassette encoding nonspecific scramble sequence was used as a negative control.

Preparation of recombinant adenovirus vectors. Adenovirus producing enhanced green fluorescent protein (eGFP), myc-tagged DOC2b (wild type, CIM mutant), and shRNA (DOC2b, control) were prepared using an AdEasy adenovirus vector system according to the manufacturer's instructions (Stratagene, Cedar Creek, TX). All amplified viruses were purified by the cesium chloride centrifugation method and stored at -80°C .

Live cell imaging of DOC2b. The pGFP-DOC2b was electroporated into 3T3-L1 adipocytes, which were then reseeded onto 0.1-mm glass-bottom dishes (Matsunami, Tokyo, Japan). At 24–48 h after electroporation, cells were serum starved for 3–4 h in DMEM and then incubated at 37°C for 2 h in Krebs-Ringer HEPES buffer (130 mmol/l NaCl, 5 mmol/l KCl, 1.3 mmol/l CaCl_2 , 1.3 mmol/l MgSO_4 , 25 mmol/l HEPES [pH 7.4]). The cells were treated with 100 nmol/l of insulin at 37°C for the time indicated and observed by laser confocal microscopy (LSM510 Pascal; Carl Zeiss, Oberkochen, Germany). For the translocation analysis, fluorescent intensities at three distinct areas in plasma membrane, cytosol, and nucleus (nine areas per cell each) of three independent cells were analyzed by Photoshop software CS2.

Yeast two-hybrid screening. The Matchmaker Yeast Two-Hybrid System (Clontech) was used for determination of DOC2b-binding partners. Full-length DOC2b and munc18c cDNA were subcloned into a pLexA vector and full-length syntaxin-4 and munc18c cDNA into a pB42AD vector. A standard lithium acetate/single-stranded carrier DNA/polyethylene glycol method for transformation into yeast strain EGY48 (p8op-lacZ) was used, and these proteins were expressed in this strain. Transcriptional activation of LacZ was determined by an X-Gal assay. β -Galactosidase activity was detected within 16 h of reaction at 30°C.

In vitro GST pull-down assay. Glutathione S-transferase (GST) fusion proteins of wild-type and CIM DOC2b were purified according to the manufacturer's instructions. GST syntaxin-4 was cleaved with PreScission Protease (2 units/ μ l) (GH Healthcare) in buffer containing 50 mmol/l Tris-HCl (pH 7.0), 150 mmol/l NaCl, 1 mmol/l EDTA, and 1 mmol/l dithiothreitol at 4°C for 16 h.

At the end of incubation, cleaved syntaxin-4 protein was further purified using Amicon Ultra filter devices (Millipore, Danvers, MA).

Recombinant individual GST-DOC2bs or GST (1 μ g each) were incubated with 1 μ g of recombinant syntaxin-4 in 1 ml of Tris-buffered saline (20 mmol/l Tris, pH 7.4, 150 mmol/l NaCl) plus 0.5% Triton X-100 in the presence of 2 mmol/l EDTA or 1 mmol/l CaCl_2 for 4–6 h. This mixture was immunoprecipitated by incubating with Glutathione Sepharose 4B (GE Healthcare) for 1 h. The precipitates were washed four times and analyzed by SDS-PAGE and immunoblotting. Approximately 5% of syntaxin-4 was pulled down by the GST-DOC2b.

Northern blotting. Total RNAs were prepared from 3T3-L1 fibroblasts, 3T3-L1 adipocytes (days 3 and 9 of differentiation) or rat epididymal fat, and mouse brain using ISOGEN (Nippongene, Tokyo, Japan) and denatured in formaldehyde/formamide, resolved by electrophoresis, and transferred to hybrid-N membranes (GH Healthcare). The membranes were hybridized with α -[^{32}P]-labeled full-length DOC2a and DOC2b cDNAs as probes and then washed three times with $1\times$ saline sodium citrate buffer (15 mmol/l NaCl, 15 mmol/l sodium citrate [pH 7.0], and 0.1% SDS) at 65°C. Radioisotopic measurements were conducted using a Phosphorimager FLA2000 (Fuji film, Tokyo, Japan).

Immunoprecipitation and immunoblotting. A 10-cm plate of cells was lysed in 1 ml of lysis buffer (20 mmol/l HEPES [pH 7.2], 100 mmol/l NaCl, 25 mmol/l NaF, 1 mmol/l sodium vanadate, 1 mmol/l benzamide, 5 μ g/ml leupeptin, 5 μ g/ml aprotinin, 1 mmol/l phenylmethylsulfonyl fluoride, 1 mmol/l dithiothreitol, and 0.5% NP-40) in the presence of 2 mmol/l EDTA or 1 mmol/l CaCl_2 and centrifuged for 15 min at 15,000g. The postnuclear lysates were used for the following experiments. The protein concentration was measured with a bicinchoninic acid protein assay reagent (Pierce, IL). For immunoprecipitation, the cell lysates were preincubated with protein-G/A-Sepharose at 4°C for 30 min to remove nonspecific bound proteins. Then, samples were incubated with primary antibodies at 4°C for 8–12 h followed by incubation with protein-G/A-Sepharose. Lysates and immunoprecipitates were resolved by SDS-PAGE and transferred to a polyvinylidene fluoride membrane (GH Healthcare). The membranes were incubated with primary antibodies for 8–12 h. Protein signals were visualized using horseradish peroxidase-conjugated secondary antibodies and an enhanced chemiluminescence substrate kit (GH Healthcare). The efficiencies of immunoprecipitation of the associated protein in Fig. 3C–E were \sim 1, 0.5, and 0.6%, respectively. All the images in figures are representative, and we repeated the immunoblots at least three times and found similar results.

Immunofluorescence microscopy and digital image analysis. Differentiated 3T3-L1 adipocytes were left untreated or electroporated by eGFP-DOC2b (wild type, CIM, Δ MID, Δ C2A, and Δ C2B), eGFP alone, DsRed2-DOC2b (wild type, CIM), shRNAs (control, DOC2b), or myc-GLUT4-eGFP. The cells were then replated onto coverslips and allowed to recover for 48 h. Cells were preincubated in the presence or absence of 50 μ mol/l BAPTA-AM for 10 min, followed by incubation with or without insulin for 20 min at 37°C. Next, the cells were fixed with 3.7% formaldehyde in PBS and permeabilized with buffer A (0.5% Triton X-100, 1% FBS in PBS) for 15 min. For the detection of endogenous proteins, the coverslips were incubated for 2 h with primary antibodies at room temperature. The cells were washed and incubated with an appropriate secondary antibody for 30 min. The coverslips were washed thoroughly again and mounted on glass slides. Immunostained cells were observed at room temperature with an LSM 5 PASCAL laser-scanning confocal microscope and its two-channel-scanning module (Carl Zeiss) equipped with an inverted Zeiss Axiovert 200M using the 63 \times oil objective lens (numerical aperture 1.4) run by LSM 5 processing software and Adobe Photoshop CS2. At least five cells were observed in a condition. The experiments were repeated at least three times, unless stated otherwise. All the images in figures are representative, and the conclusions are based on qualitative visual impression. The cell surface myc-GLUT4-eGFP was measured by subtracting the internal myc signal from total myc signal of electroporated cells. The plasma membrane eGFP content was also measured. The cell surface GLUT4 was calculated as (total myc – internal myc)/(total eGFP – internal eGFP) (22).

2-Deoxy-glucose uptake. Differentiated adipocytes were prepared in 24-well plates. Cells were infected with the recombinant adenoviruses. Two days thereafter, the cells were serum starved for 2 h at 37°C in Krebs-Ringer HEPES buffer. Then, the cells were stimulated with or without 100 nmol/l of insulin for 10 min, and 2-deoxy-glucose uptake was determined by 2-deoxy-D-[2,6- ^3H] glucose incorporation. Nonspecific glucose uptake was measured in the presence of 20 μ mol/l cytochalasin B and subtracted from each determination to obtain specific uptake. The results were normalized by the protein amount.

Statistical analysis. Multiple comparisons among groups were performed using one-way ANOVA (post hoc test: Tukey-Kramer). Results are presented as means \pm SD. Values of $P < 0.05$ were considered statistically significant.




FIG. 1. The expression profiles and intracellular localization of DOC2b in 3T3-L1 adipocytes. **A:** The expressions of DOC2a and DOC2b in 3T3-L1 fibroblasts, 3T3-L1 adipocytes (days 3 and 9 of differentiation), rat epididymal fat, and mouse brain were analyzed by mRNA blot. **B:** Differentiated 3T3-L1 adipocytes were serum-starved for 3–4 h and then stimulated with 100 nmol/l of insulin for 20 min, fixed, and immunostained. The endogenous DOC2b and GLUT4 were visualized using anti-DOC2b and anti-GLUT4 antibodies and observed by confocal microscopy. (Please see <http://dx.doi.org/10.2337/db08-0303> for a high-quality digital representation of this figure.)

RESULTS

DOC2b translocates to the plasma membrane in response to insulin. Type C tandem C2 domain proteins are classified into three groups (i.e., synaptotagmin and synaptotagmin-like protein and DOC2 family proteins). The first two groups of proteins regulate relatively fast membrane fusion (on the order of milliseconds to a few seconds) (12,13). This time scale is not suitable for GLUT4 vesicle fusion. Therefore, we focused on DOC2 family proteins as candidate regulators of GLUT4 vesicle fusion. First, we determined the expression profile of DOC2 mRNA in adipocytes. As shown in Fig. 1A, DOC2a was not expressed in 3T3-L1 adipocytes. According to a previous study, DOC2 γ is localized to the nucleus and has no Ca²⁺-binding activity because of amino acid substitutions at the Ca²⁺-binding sites (14). Thus, we investigated the function of the DOC2b isoform involved in GLUT4 membrane fusion. Next, we examined the intracellular localization of DOC2b in differentiated 3T3-L1 adipocytes using anti-DOC2b antibody (Fig. 1B) or by expressing an eGFP fused to DOC2b (Fig. 2A). As shown in Fig. 1B, DOC2b results in a fine punctate or granular appearance throughout the cytoplasm under basal conditions. In contrast, the addition of insulin yields relatively slow (~5 min) translocation of DOC2b to the cell periphery (Fig. 2A). This time scale of translocation was very similar to that of GLUT4 vesicles. It is noteworthy that deletion of the MID enhanced plasma membrane localization even in the absence of insulin and that the C2B domain is necessary for membrane targeting (Fig. 2B). These observations are interesting in considering the distinct roles of the C2A and C2B domains and the negative regulatory function of MID. We performed additional experiments to determine the role of calcium in the translocation of DOC2b. As shown in Fig. 2C, the cell membrane permeable Ca²⁺-chelating




FIG. 2. Insulin augments DOC2b translocation to the plasma membrane. **A:** 3T3-L1 adipocytes were electroporated with eGFP-DOC2b and then treated with 100 nmol/l of insulin for the times indicated. Live fluorescent images of the cells were captured by confocal microscopy. Relative fluorescence of the plasma membrane, nucleus, and cytosol were each measured in three distinct areas. At least three cells were analyzed for each condition. Results are means \pm SD from three independent experiments. **B:** 3T3-L1 adipocytes expressing eGFP-DOC2b (WT [wild type], Δ MID, Δ C2A, or Δ C2B) were treated with or without 100 nmol/l of insulin and observed by confocal microscopy. **C:** 3T3-L1 adipocytes were electroporated with eGFP-DOC2b and then pretreated with 50 μ mol/l of BAPTA-AM for 10 min, before treatment with insulin and observed under a confocal microscope.




FIG. 3. Insulin promotes Ca^{2+} -dependent interaction between DOC2b and syntaxin-4. **A:** pLexA containing DOC2b or munc18c and pB42AD containing munc18c, syntaxin-4 (synt.4) or empty vectors were coexpressed in the yeast strain of EGY48 (p8op-lacZ), followed by incubation at 30°C for 16 h. Transcriptional activation of LacZ was determined by β -galactosidase assay. **B:** GST-tagged DOC2b and syntaxin-4 were bacterially expressed. Syntaxin-4 protein was cleaved by PreScission protease and further purified with Amicon Ultra filter devices. Both proteins ($1\ \mu\text{g}$ each) were mixed in Tris-buffered saline in the presence of $2\ \text{mmol/l}$ EDTA or $1\ \text{mmol/l}$ CaCl_2 and pulled down by glutathione sepharose. The precipitates were analyzed by Western blotting with anti-syntaxin-4 and anti-GST antibodies. **C:** 3T3-L1 adipocytes were serum-starved for 3–4 h and pretreated with or without $50\ \mu\text{mol/l}$ of BAPTA-AM before insulin treatment. The DOC2b–syntaxin-4 interaction was determined by immunoprecipitation using anti-DOC2b antibody. The immunoprecipitated proteins were immunoblotted with anti-syntaxin-4 and anti-DOC2b antibodies. **D and E:** Myc-tagged DOC2b was expressed by adenovirus vector in 3T3-L1 adipocytes. After serum starvation and pretreatment with or without $50\ \mu\text{mol/l}$ of BAPTA-AM, before insulin treatment, the cells were stimulated with or without $100\ \text{nmol/l}$ of insulin for 20 min and then immunoprecipitated with anti-myc or anti-syntaxin-4 antibodies. The immunoprecipitated proteins were immunoblotted with anti-myc and anti-syntaxin-4 antibodies.

agent BAPTA-AM inhibited insulin-dependent translocation of DOC2b.

DOC2b binds syntaxin-4 upon stimulation with insulin. Since DOC2b is thought to be a soluble calcium-sensing protein, compartment-specific targeting must be achieved through interaction with membrane-bound proteins such as SNARE and SNARE-related proteins. Therefore, we attempted to identify DOC2b-binding partners among these proteins using a yeast two-hybrid system. We found a very strong interaction between DOC2b and syntaxin-4 compared with the already known binding between munc18c and syntaxin4 (Fig. 3A). Interestingly, this t-SNARE protein is reportedly a key molecule for GLUT4 vesicle fusion in response to insulin (5,15). Although this interaction was very strong, SNARE proteins are quite “sticky” and can on occasion bind with many proteins nonspecifically. Therefore, we performed the following three additional experiments. First, we determined the direct interaction *in vitro* using recombinant proteins, GST-tagged DOC2b, and synthesized syntaxin-4. As shown in Fig. 3B, the interaction was easily detected by immunoblotting in the presence of calcium. Second, we examined endogenous protein-protein interactions by immunoprecipitation experiments using polyclonal anti-DOC2b. As shown in Fig. 3C, insulin treatment increased DOC2b–syntaxin-4 binding, and BAPTA-AM abolished this interaction. Since the molecular weights of DOC2b and the IgG heavy chain are quite similar (computed molecular

weight of DOC2b and syntaxin-4 are 46 and 34 kDa, respectively), it was difficult to perform a reverse immunoprecipitation experiment. Third, our results were confirmed by immunoprecipitation experiments using adipocytes expressing myc-tagged DOC2b (Fig. 3D and E). It is important to note that we could not detect the interaction between DOC2b and syntaxin-4 in the buffer containing EDTA (data not shown). Furthermore, we could not find interaction between DOC2b and syntaxin6 in 3T3-L1 adipocytes (online appendix Fig. S2).

To better assess the calcium dependency of DOC2b translocation and interaction with syntaxin-4 in adipocytes, we conducted the following additional experiments using a Ca^{2+} -unbound mutant. Based on the information from crystallographic analysis of synaptotagmin-1 (16–18), we created mutations in the putative Ca^{2+} -binding sites of DOC2b (i.e., C2A [D157N, D163N] and C2B [D297N, D303N]) and designated the product obtained the CIM (Fig. 4A). This type of mutant reportedly loses its calcium-dependent phospholipids-targeting capacity (19,20). As shown in Fig. 4B, the CIM mutation markedly inhibited insulin-induced DOC2b translocation. Furthermore, CIM-DOC2b also failed to interact with syntaxin-4 in both the *in vivo* and the *in vitro* setting (Fig. 4C–E). These results raise the possibility that Ca^{2+} binding is essential for insulin-stimulated DOC2b translocation as well as the interaction with syntaxin-4.




FIG. 4. Calcium binding to DOC2b is essential for its translocation and interaction with syntaxin-4. **A:** ClustalW sequence alignment of C2A and C2B domains from synaptotagmin-1, -2, -3, -5, and -9 and DOC2a and DOC2b. Two aspartic acid residues in each C2 domain (shown on a black background) are well-conserved putative Ca²⁺-binding sites. These four aspartic acid residues were mutated into asparagine for CIM-DOC2b (D157N, D163N, D297N, and D303N) construction. **B:** Wild-type (WT) or calcium-interacting domain mutants (CIM) of eGFP-DOC2b were expressed in 3T3-L1 adipocytes, which were then treated with insulin and observed under a confocal microscope. Figures show representative images of three independent experiments. **C:** Purified GST-DOC2b (WT or CIM) and syntaxin-4 were mixed in the presence of 2 mmol/l EDTA or 1 mmol/l of CaCl₂ and pulled down with glutathione sepharose. The precipitates were analyzed by Western blotting with anti-syntaxin-4 and anti-GST antibodies. **D** and **E:** Myc-tagged DOC2b (WT or CIM) was expressed in 3T3-L1 adipocytes. After serum starvation, the cells were stimulated with or without 100 nmol/l of insulin for 20 min and then immunoprecipitated with anti-myc or anti-syntaxin-4 antibodies. The immunoprecipitated proteins were immunoblotted with anti-myc and anti-syntaxin-4 antibodies.

DOC2b regulates the step of GLUT4 vesicle fusion in response to insulin. One interpretation of the above findings is that DOC2b may act as a Ca²⁺ sensor protein for SNARE complexes triggering GLUT4 vesicle fusion. To assess the role of DOC2b in GLUT4 vesicle fusion to the plasma membrane, we utilized a GLUT4 construct containing four myc epitopes in the first exofacial loop of GLUT4 and an eGFP fusion at its cytoplasmic COOH terminus. These exofacial tags are easily detected by anti-myc antibody but only when GLUT4 vesicles are fused to the plasma membrane (21). Adipocytes expressing this GLUT4 construct and DsRed2-DOC2b (wild type or CIM) or shRNAs were observed by confocal microscopy. As shown in Fig. 5A and B, the externalized GLUT4 was increased in the cells coexpressing wild-type DOC2b, while being de-

creased in those coexpressing CIM-DOC2b or shRNA (shRNA_{DOC2b}) compared with the control cells. Since the above conclusions were based on qualitative visual impression, we next estimated the fluorescent signals of the cellular rims in Fig. 5A and B in two ways. First, we counted the number of the cells with eGFP rims (50 cells in each condition) in the cells expressing myc-GLUT4-eGFP. As shown in Fig. 5C, just translocated or docked GLUT4 detected by eGFP fluorescence did not change under either condition. Second, we quantified the ratio of cell surface GLUT4 (myc signal) to GLUT4 translocated to plasma membrane (eGFP signal) as previously described (22). As shown in Fig. 5D and E, cell surface GLUT4 was increased in the cells expressing wild-type DOC2b but decreased in those expressing CIM-DOC2b and silenced DOC2b (Fig. 5D and E). These results, taken together with the data shown in Fig. 5A, are consistent with the idea that DOC2b is a calcium-sensing protein and regulates the GLUT4 vesicle fusion step in response to insulin.

Role of DOC2b in glucose transport in 3T3-L1 adipocytes. We next focused on the role of DOC2b in insulin-dependent glucose uptake in adipocytes expressing wild-type DOC2b and CIM-DOC2b. As shown in Fig. 6A, overexpression of wild-type DOC2b increased insulin-stimulated glucose uptake to 122% of the control level. In contrast, overexpression of CIM-DOC2b decreased to 78% of the control level. Furthermore, we introduced shRNAs (shRNA_{DOC2b, control}) by adenovirus vectors into cultured adipocytes to induce specific degradation of the DOC2b mRNA. DOC2b protein expression was decreased to 50 and 10% of the control level in the cells infected with viruses at multiplicity of infection (MOI) of 20 and 50, respectively (Fig. 6B). As expected, glucose uptake was decreased from 87 to 60% in adipocytes infected with the adenovirus vectors at MOI of 20–50 (Fig. 6B). To confirm the specificity of silencing, we conducted add-back style rescue experiment using adenovirus vector containing wild-type DOC2b. As shown in online appendix Fig. S3, overexpression of DOC2b rescued the inhibitory effect on glucose uptake in DOC2b-silenced cells. Under these conditions, DOC2b overexpression and silencing had no effects on serine phosphorylation of Akt (Fig. 6A and B and online appendix Fig. S3). These results, taken together with the data presented in Figs. 2–5, suggest that DOC2b regulates glucose transport through modulating vesicle fusion processes but not insulin signaling.

DISCUSSION

Regulation of glucose uptake in muscle and adipose tissues by insulin is of fundamental importance for proper maintenance of postprandial hyperglycemia. This hormone stimulates translocation of the GLUT4 glucose transporter from the intracellular membrane to the cell surface (1,2). In addition to this movement of intracellular vesicles containing GLUT4, it has been suggested that the docking and fusion step of GLUT4 vesicles is also critically regulated by insulin (3,4,23). However, the precise mechanism by which insulin regulates vesicle fusion is still largely unknown.

A key finding of this study is identification of the double C2 domain protein DOC2b, which mediates insulin-regulated GLUT4 vesicle fusion. Like other membrane fusion processes, GLUT4 vesicle fusion occurs essentially through the formation of a “core complex” consisting of syntaxin-4 and VAMP-2 (5). In general, however, a number of additional factors are required to bring about SNARE-mediated membrane fusion in vivo. Many of these factors,




FIG. 5. DOC2b enhances GLUT4 vesicle fusion in 3T3-L1 adipocytes. **A** and **B**: Exofacial myc-tagged GLUT4-eGFP and DsRed2-DOC2b or pcPUR-U6i-shRNA_{DOC2b,control} were coelectroporated into 3T3-L1 adipocytes. The cells were serum starved for 2–4 h and either untreated or treated with 100 nmol/l of insulin for 20 min. The cells were then fixed and stained with anti-myc antibody and Cy5-labeled secondary antibody without detergents. In the cells electroporated with shRNAs, endogenous DOC2b were visualized with anti-DOC2b antibody, followed by Cy3-labeled secondary antibody. Stained cells were observed by confocal microscopy. This shRNA system decreased DOC2b protein expression to 10–20% of control level. Images are representative of three independent experiments. **C–E**: Percents of cells with GLUT4-eGFP rims and the cell surface myc-GLUT4 contents (the ratio of myc signal/eGFP signal at plasma membrane rims) in Fig. 5A was calculated as described under RESEARCH DESIGN AND METHODS. **C**: □, -insulin; ■, +insulin. **D**: □, control; ▨, wild type; ■, CIM. **E**: □, shRNA control; ■, shRNA DOC2b. The graphs represent values from at least 3–5 independent experiments, and error bars show SD. (Please see <http://dx.doi.org/10.2337/db08-0303> for a high-quality digital representation of this figure.)

which can collectively be called SNARE regulators (e.g., munc18, synaptotagmin, munc13, GATE-16/Agp8, LMA1, synaptophysin, tomosyn, and Vsm1/Ddi1), bind directly to SNARE proteins and are involved in membrane trafficking and fusion events (24). Among these SNARE regulators,

munc18c and tomosyn were reported to be negative regulators of the SNARE complex assembly involved in GLUT4 vesicle fusion (25–27). Despite numerous investigations, the positive SNARE regulators for GLUT4 vesicle fusion have not been adequately clarified. In this report, we have shown that




FIG. 6. DOC2b regulates insulin-stimulated glucose uptake in 3T3-L1 adipocytes. 3T3-L1 adipocytes were infected with recombinant adenovirus vectors encoding eGFP, myc-tagged DOC2b (WT, CIM) at MOI of 50 (*A* and *B*) or adenovirus vectors encoding shRNA specific for DOC2b or nontargeting control at MOI of 0, 20, and 50 (*C* and *D*). After serum starvation, the cells were treated with or without 100 nmol/l of insulin for 10 min. *A*: □, control; ▨, wild type; ■, CIM. *C*: □, 0; ▨, 20; ■, 50. 2-Deoxy-glucose uptake was measured under each condition. Results are presented as means \pm SD of at least five independent experiments. *B* and *D*: The cell lysates were also immunoblotted with anti-myc, anti-GFP, anti-DOC2b, anti-Akt, anti-phosphoserine-Akt, and anti-glyceraldehyde-3-phosphate dehydrogenase antibodies. Immunoblots were representative of at least three independent experiments.

DOC2b mediates insulin-stimulated GLUT4 membrane fusion in adipocytes, while having no effect on the GLUT4 vesicle translocation step. These data are consistent with the hypothesis that DOC2b regulates insulin-stimulated GLUT4 vesicle fusion. DOC2b may be a positive SNARE regulator for vesicle fusion processes in adipocytes.

A second significant finding reported herein is the identification of a DOC2b binding partner. DOC2b interacts with t-SNARE syntaxin-4 upon stimulation with insulin in the presence of calcium. Syntaxin-4 is thought to be a SNARE protein on the target membrane for GLUT4 vesicle fusion (28,29). As shown in Fig. 3A, this interaction appears to be very strong compared with that between munc18c and syntaxin-4 demonstrated by the yeast two-hybrid method. Although this interaction appeared to be very strong, SNARE proteins are quite sticky and can on occasion bind with many proteins nonspecifically. Therefore, we performed three additional experiments. As shown in Fig. 3B–E, we confirmed the interaction between DOC2b and syntaxin-4 in both the *in vivo* and the *in vitro* setting. Furthermore, changes in the intracellular localization of DOC2b also supported the functional interaction. As shown in Fig. 2A, DOC2b translocates to the plasma membrane in response to insulin stimulation. Importantly, the time scale of DOC2b translocation coincides with relatively slow externalization of GLUT4 vesicles. Taken together, our data are consistent with the aforementioned hypothesis that DOC2b regulates GLUT4 vesicle fusion by triggering SNARE complex assembly.

Another interesting observation made in this study is the essential role of $[Ca^{2+}]_i$ in insulin-stimulated GLUT4 vesicle fusion. In 2001, Whitehead et al. (8) first reported that a

calcium chelator, BAPTA-AM, inhibited GLUT4 externalization and glucose uptake. However, the precise mechanism underlying calcium-dependent GLUT4 vesicle fusion remains unknown because no studies have as yet focused on Ca^{2+} -sensing proteins in adipocytes. DOC2b is structurally similar to the well-known calcium-sensing SNARE regulator synaptotagmins (Fig. 4A). Taking these observations together, we hypothesized that DOC2b is a Ca^{2+} -sensing protein that regulates GLUT4 vesicle fusion in adipocytes. To better assess the role of Ca^{2+} in GLUT4 vesicle fusion, we confirmed the following. First, DOC2b translocation and its binding to syntaxin-4 were shown to be $[Ca^{2+}]_i$ dependent. Second, mutations in calcium-binding sites on C2 domains of DOC2b resulted in loss of syntaxin-4 binding, GLUT4 externalization, and glucose uptake. In contrast, we also observed DOC2b–syntaxin-4 binding, without insulin action, in a GST pull-down assay, suggesting that $[Ca^{2+}]_i$ is necessary for this interaction *in vitro* (Fig. 3B). In parallel, we also found that insulin initiates the DOC2b translocation to plasma membrane and promotes interaction between DOC2b and syntaxin-4 in the presence of Ca^{2+} ions. Based on the above observations, we propose a simple model whereby insulin regulates SNARE regulator DOC2b, and basal level of $[Ca^{2+}]_i$ may act in a constitutive manner to promote DOC2b–syntaxin-4 interaction involved in insulin-stimulated GLUT4 vesicle fusion.

A recent report (30) suggests that DOC2 proteins remove munc18 from syntaxin, thereby regulating core SNARE complex formation. This interpretation is very attractive because munc18c is thought to be a negative regulator of GLUT4 vesicle fusion. Although we have no direct data pertaining to

munc18c, it is possible that munc18c and DOC2b may modulate SNARE assembly in a counterregulatory manner. Very recently, Ke et al. (31) reported that DOC2b bound munc18c, but not syntaxin-4, in pancreatic β -cells. This apparent discrepancy on syntaxin-4 binding may be attributable to the different experimental conditions. They performed most of their experiments using a buffer without calcium (i.e., Nonidet P-40 lysis buffer). Since DOC2b has conserved Ca^{2+} -binding sites and is thought to be a Ca^{2+} sensor protein in other cell types such as neuron (32) and chromaffin cells (33), Ca^{2+} might be important for the physiological properties of DOC2b in β -cells. Further work is required to uncover the underlying mechanisms by which DOC2b regulates SNARE assembly in response to insulin.

In summary, we have identified DOC2b as a syntaxin-4 binding protein in adipocytes. This protein regulates GLUT4 vesicle fusion as well as glucose uptake in response to insulin stimulation. We have further revealed that DOC2b requires $[\text{Ca}^{2+}]_i$ and positively regulates the step of GLUT4 vesicle fusion.

ACKNOWLEDGMENTS

This work was partly supported by grants-in-aid for scientific research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (to M.E. and Y.T.); from the Takeda Scientific Foundation (to M.E.); and by the Research Grant for Longevity Science (to Y.T.).

No potential conflicts of interest relevant to this article were reported.

We thank Dr. R.R. Duncan for the DOC2a,b constructs, Dr. T. Takuma for the munc18c construct, Dr. K. Taira for the pcPUR+U6i cassette, and Dr. M. Fukuda for the anti-DOC2b antibody. We are also very grateful to Dr. Teruo Nishida for generously supporting us in the experiments using the confocal microscope and to Y. Kora, M. Kaneko, K. Yamada, and S. Ota for their technical supports.

REFERENCES

- Yang J, Holman GD: Comparison of GLUT4 and GLUT1 subcellular trafficking in basal and insulin-stimulated 3T3-L1 cells. *J Biol Chem* 268:4600–4603, 1993
- Czech MP, Corvera S: Signaling mechanisms that regulate glucose transport. *J Biol Chem* 274:1865–1868, 1999
- Koumanov F, Jin B, Yang J, Holman GD: Insulin signaling meets vesicle traffic of GLUT4 at a plasma-membrane-activated fusion step. *Cell Metab* 2:179–189, 2005
- Gonzalez E, McGraw TE: Insulin signaling diverges into Akt-dependent and -independent signals to regulate the recruitment/docking and the fusion of GLUT4 vesicles to the plasma membrane. *Mol Biol Cell* 17:4484–4493, 2006
- Cheatham B, Chuk AV, Kahn CR, Wang L, Rhodes CJ, Klip A: Insulin-stimulated translocation of GLUT4 glucose transporters requires SNARE-complex proteins. *Proc Natl Acad Sci U S A* 93:15169–15173, 1996
- Burgoyne RD, Morgan A: Secretory granule exocytosis. *Physiol Rev* 83:581–632, 2003
- Tucker WC, Weber T, Chapman ER: Reconstitution of Ca^{2+} -regulated membrane fusion by synaptotagmin and SNAREs. *Science* 304:435–438, 2004
- Whitehead JP, Molero JC, Clark S, Meneilly MS, James DE: The role of Ca^{2+} in insulin-stimulated glucose transport in 3T3-L1 cells. *J Biol Chem* 276:27816–27824, 2001
- Perin MS, Fried VA, Mignery GA, Jahn R, Sudhof TC: Phospholipid binding by a synaptic vesicle protein homologous to the regulatory region of protein kinase C. *Nature* 345:260–263, 1990
- Rickman C, Craxton M, Osborne S, Davletov B: Comparative analysis of tandem C2 domains from the mammalian synaptotagmin family. *Biochem J* 378:681–686, 2004
- Miyagishi M, Taira K: U6 promoter-driven siRNAs with four uridine 3' overhangs efficiently suppress targeted gene expression in mammalian cells. *Nat Biotechnol* 20:497–500, 2002
- Kuroda TS, Fukuda M: Rab27A-binding protein Slp2-a is required for peripheral melanosome distribution and elongated cell shape in melanocytes. *Nat Cell Biol* 6:1195–1203, 2004
- Hui E, Bai J, Wang P, Sugimori M, Llinas RR, Chapman ER: Three distinct kinetic groupings of the synaptotagmin family: candidate sensors for rapid and delayed exocytosis. *Proc Natl Acad Sci U S A* 102:5210–5214, 2005
- Fukuda M, Saegusa C, Kanno E, Mikoshiba K: The C2A domain of double C2 protein γ contains a functional nuclear localization signal. *J Biol Chem* 276:24441–24444, 2001
- Volchuk A, Wang Q, Ewart HS, Liu Z, He L, Bennett MK, Klip A: Syntaxin 4 in 3T3-L1 adipocytes: regulation by insulin and participation in insulin-dependent glucose transport. *Mol Biol Cell* 7:1075–1082, 1996
- Sutton RB, Davletov BA, Berghuis AM, Sudhof TC, Sprang S: Structure of the first C2 domain of synaptotagmin I: a novel Ca^{2+} /phospholipid-binding fold. *Cell* 80:929–938, 1995
- Shao X, Davletov BA, Sutton RB, Sudhof TC, Rizo J: Bipartite Ca^{2+} -binding motif in C2 domains of synaptotagmin and protein kinase C. *Science* 273:248–251, 1996
- Fernandez I, Arac D, Ubach J, Gerber SH, Shin O, Gao Y, Anderson R, Sudhof TC, Rizo J: Three-dimensional structure of the synaptotagmin I C2B-domain: synaptotagmin I as a phospholipid binding machine. *Neuron* 32:1057–1069, 2001
- Fukuda M, Kojima T, Mikoshiba K: Regulation by bivalent cations of phospholipid binding to the C2A domain of synaptotagmin III. *Biochem J* 323:421–425, 1997
- Mackler JM, Drummond JA, Loewen CA, Robinson IM, Reist NE: The C_2B Ca^{2+} -binding motif of synaptotagmin is required for synaptic transmission in vivo. *Nature* 418:340–344, 2002
- Bogan JS, McKee AE, Lodish HF: Insulin-responsive compartments containing GLUT4 in 3T3-L1 and CHO cells: regulation by amino acid concentrations. *Mol Cell Biol* 21:4785–4806, 2001
- Park JG, Bose A, Leszyk J, Czech MP: PYK2 as a mediator of endothelin-1/G α 11 signaling to GLUT4 glucose transporters. *J Biol Chem* 276:47751–47754, 2001
- Lizunov VA, Matsumoto H, Zimmerberg J, Cushman SW, Frolov VA: Insulin stimulates the halting, tethering, and fusion of mobile GLUT4 vesicles in rat adipose cells. *J Cell Biol* 169:481–489, 2005
- Gerst JE: SNARE regulators: matchmakers and matchbreakers. *Biochim Biophys Acta* 1641:99–110, 2003
- Thurmond DC, Ceresa BP, Okada S, Elemendorf JS, Coker K, Pessin JE: Regulation of insulin-stimulated GLUT4 translocation by Munc18c in 3T3-L1 adipocytes. *J Biol Chem* 273:33876–33883, 1998
- Kanda H, Tamori Y, Shinoda H, Yoshikawa M, Sakae M, Udagawa J, Otani H, Tashiro F, Miyazaki J, Kasuga M: Adipocytes from Munc18c-null mice show increased sensitivity to insulin-stimulated GLUT4 externalization. *J Clin Invest* 115:291–301, 2005
- Widberg CH, Bryant NJ, Girotti M, Res S, James DE: Tomosyn interacts with the t-SNAREs syntaxin4 and SNAP23 and plays a role in insulin-stimulated GLUT4 translocation. *J Biol Chem* 278:35093–35101, 2003
- Tellam JT, Macaulay SL, McIntosh S, Hewish DR, Ward CW, James DE: Characterization of munc-18c and syntaxin-4 in 3T3-L1 adipocytes. *J Biol Chem* 272:6179–6186, 1997
- Yang C, Coker KJ, Kim JK, Mora S, Thurmond DC, Davis AC, Yang B, Williamson RA, Shulman GI, Pessin JE: Syntaxin 4 heterozygous knockout mice develop muscle insulin resistance. *J Clin Invest* 107:1311–1318, 2001
- Verhage M, de Vries KJ, Roshol H, Burbach JP, Gispen WH, Sudhof TC: DOC2 proteins in rat brain: complementary distribution and proposed function as vesicular adapter proteins in early stages of secretion. *Neuron* 18:453–461, 1997
- Ke B, Oh E, Thurmond DC: Doc2beta is a novel munc18c-interacting partner and positive effector of syntaxin 4-mediated exocytosis. *J Biol Chem* 282:21786–21797, 2007
- Groffen AJ, Friedrich R, Brian EC, Ashery U, Verhage M: DOC2A and DOC2B are sensors for neuronal activity with unique calcium-dependent and kinetic properties. *J Neurochem* 97:818–833, 2006
- Friedrich R, Groffen AJ, Connell E, van Weering JR, Gutman O, Henis YI, Davletov B, Ashery U: DOC2B acts as a calcium switch and enhances vesicle fusion. *J Neurosci* 28:6794–6806, 2008

Increased insulin demand promotes while pioglitazone prevents pancreatic beta cell apoptosis in *Wfs1* knockout mice

M. Akiyama · M. Hatanaka · Y. Ohta · K. Ueda ·
A. Yanai · Y. Uehara · K. Tanabe · M. Tsuru ·
M. Miyazaki · S. Saeki · T. Saito · K. Shinoda · Y. Oka ·
Y. Tanizawa

Received: 7 May 2008 / Accepted: 29 December 2008 / Published online: 4 February 2009
© Springer-Verlag 2009

Abstract

Aims/hypothesis The *WFS1* gene encodes an endoplasmic reticulum (ER) membrane-embedded protein called Wolfram syndrome 1 protein, homozygous mutations of which cause selective beta cell loss in humans. The function(s) of this protein and the mechanism by which the mutations of this gene cause beta cell death are still not fully understood. We hypothesised that increased insulin demand as a result of obesity/insulin resistance causes ER stress in pancreatic beta cells, thereby promoting beta cell death.

Methods We studied the effect of breeding *Wfs1*^{-/-} mice on a C57BL/6J background with mild obesity and insulin resistance, by introducing the agouti lethal yellow mutation (*A^{y/a}*). We also treated the mice with pioglitazone.

Results *Wfs1*^{-/-} mice bred on a C57BL/6J background rarely develop overt diabetes by 24 weeks of age, showing only mild beta cell loss. However, *Wfs1*^{-/-} *A^{y/a}* mice developed selective beta cell loss and severe insulin-deficient diabetes as early as 8 weeks. This beta cell loss was due to apoptosis. In *Wfs1*^{+/+} *A^{y/a}* islets, levels of ER chaperone immunoglobulin-binding protein (BiP)/78 kDa glucose-regulated protein (GRP78) and phosphorylation of eukaryotic translation initiation factor 2, subunit α (eIF2 α) apparently increased. Levels of both were further increased in *Wfs1*^{-/-} *A^{y/a}* murine islets. Electron micrography revealed markedly dilated ERs in *Wfs1*^{-/-} *A^{y/a}* murine beta cells. Interestingly, pioglitazone treatment protected beta cells from apoptosis and almost completely prevented diabetes development.

Electronic supplementary material The online version of this article (doi:10.1007/s00125-009-1270-6) contains supplementary material, which is available to authorised users.

M. Akiyama · M. Hatanaka · Y. Ohta · K. Tanabe · M. Tsuru ·
M. Miyazaki · Y. Tanizawa (✉)
Division of Endocrinology, Metabolism,
Hematological Sciences and Therapeutics,
Department of Bio-Signal Analysis,
Yamaguchi University Graduate School of Medicine,
1-1-1 Minami Kogushi,
Ube, Yamaguchi 755-8505, Japan
e-mail: tanizawa@yamaguchi-u.ac.jp

K. Ueda
Health Service Center, Organization for University Education,
Yamaguchi University,
Ube, Yamaguchi, Japan

A. Yanai · K. Shinoda
Division of Neuroanatomy, Department of Neuroscience,
Yamaguchi University Graduate School of Medicine,
Ube, Yamaguchi, Japan

Y. Uehara · S. Saeki · T. Saito
Applied Medical Engineering Science,
Yamaguchi University Graduate School of Medicine,
Ube, Yamaguchi, Japan

K. Tanabe
The Japan Health Science Foundation,
Tokyo, Japan

Y. Oka
Division of Molecular Metabolism and Diabetes,
Department of Internal Medicine,
Tohoku University Graduate School of Medicine,
Sendai, Japan

Conclusions/interpretation *Wfs1*-deficient beta cells are susceptible to ER stress. Increased insulin demand prompts apoptosis in such cells in vivo. Pioglitazone, remarkably, suppresses this process and prevents diabetes. As common *WFS1* gene variants have recently been shown to confer a risk of type 2 diabetes, our findings may be relevant to the gradual but progressive loss of beta cells in type 2 diabetes.

Keywords Apoptosis · Diabetes mellitus · Endoplasmic reticulum · Endoplasmic reticulum stress · Insulin · Pancreatic beta cell · Pioglitazone · Wolfram syndrome

Abbreviations

eIF2 α	Eukaryotic translation initiation factor 2, subunit α
ER	Endoplasmic reticulum
GRP78	78 kDa Glucose-regulated protein
GRP94	94 kDa Glucose-regulated protein
ipGTT	Intraperitoneal glucose tolerance test
IRE1	Inositol-requiring protein 1
ITT	Insulin tolerance test
UPR	Unfolded protein response
WFS1	Wolfram syndrome 1
WT	Wild-type

Introduction

Many obese individuals with marked insulin resistance do not develop overt diabetes. However, in individuals destined to develop type 2 diabetes, pancreatic beta cells fail to produce enough insulin to meet systemic demand. This beta cell failure is caused by insufficient beta cell response to glucose and inadequate beta cell mass expansion [1]. Recently, several reports have convincingly confirmed the contribution of beta cell mass reduction to type 2 diabetes [2, 3], at least in its advanced stages. Although the cause of this decrease is unknown, increased apoptosis may play an important role [1, 2]. In addition to genetic factors, processes involving glucotoxicity and/or lipotoxicity are likely to be contributory [4]. Endoplasmic reticulum (ER) stress has also recently emerged as a candidate mechanism [5–7].

Wolfram syndrome is a rare recessively inherited genetic disorder, characterised by juvenile-onset diabetes mellitus and progressive optic atrophy [8]. Several neuro-psychiatric illnesses may also be present [9]. Beta cells are selectively lost from the pancreatic islets and this loss is genetically programmed [10]. Our group and others previously identified the Wolfram syndrome gene, designating it *WFS1* [11] or wolframin [12] and showing that it is localised primarily in the ER [13, 14]. Homozygous *Wfs1* knockout mice developed glucose intolerance. However, the diabetic

phenotype of the *Wfs1*^{-/-} mouse was milder than that seen in Wolfram syndrome patients and was largely dependent on genetic background [15].

Despite intensive studies, the precise function of the Wolfram syndrome 1 (WFS1) protein is still largely unknown. It may regulate ER calcium homeostasis by serving as an ER cation channel [16, 17]. Recently the WFS1 protein was also suggested to be a putative chaperone for the Na/K ATPase b1 subunit in the ER [18]. However, it is certain that its function is closely related to ER stress responses. ER stress induces *Wfs1* expression and, in turn, loss of WFS1 protein exacerbates ER stress [15, 19–21]. Furthermore, *Wfs1*^{-/-} islet cells are susceptible to ER stress-induced apoptosis [15, 21, 22]. ER stress is induced under conditions such as overload of protein synthesis/processing, accumulation of structurally abnormal proteins, disturbance of post-translational modification and ER calcium homeostasis abnormalities. When ER stress develops, cells respond by unfolded protein response (UPR), facilitating protein folding via the induction of chaperone proteins, attenuation of translations, as well as degradation of misfolded proteins, a process called ER-associated degradation [23–25]. If the stress is severe, apoptosis is induced. Accumulating evidence suggests that a high level of ER stress or defective ER stress signalling causes beta cell death and that diabetes thereby develops [26–30].

We wished to test in vivo the hypothesis that beta cell loss in *Wfs1*^{-/-} mice is caused by an inability to cope with ER stress. The agouti yellow (*A^y/a*) mouse is a genetic model of mild obesity/insulin resistance with compensatory beta cell hyperplasia [31]. In this mouse, ectopically expressed agouti protein promotes food intake and weight gain by antagonising signalling at melanocortin-4 receptor in the hypothalamus. ER stress is likely to have been induced in these beta cells by increased insulin synthesis and secretion demands, and also by elevated serum NEFA [32]. As *Wfs1*^{-/-} mice on the C57BL/6J background rarely develop overt diabetes by 24 weeks, we introduced the *A^y* mutation into C57BL/6J *Wfs1*^{-/-} mice and assessed the consequences. Furthermore, we treated *Wfs1*^{-/-} mice with pioglitazone, which ameliorates insulin resistance.

Methods

Animals All experimental protocols were approved by the Ethics of Animal Experimentation Committee at Yamaguchi University School of Medicine.

The *Wfs1*^{-/-} mice had a C57BL/6J background [15]. The Agouti yellow mice (C57BL/6J*HamSlc-A^y*) were obtained from M. Nishimura (Nagoya University Graduate School of Medicine, Nagoya, Japan) and Japan SLC

(Hamamatsu, Japan). We used male mice for all experiments. The mice were kept under standard, specific pathogen-free conditions with a constant dark/light cycle and free access to standard mouse chow (MF; Oriental Yeast, Tokyo, Japan) and water. The high-fat diet (rodent diet with 60% energy from fat; D12492) was purchased from Research Diet (New Brunswick, NJ, USA) and was freely accessible. For pioglitazone treatment, mice were fed standard mouse chow with 0.01% pioglitazone (wt/wt) from the age of 4 weeks. Pioglitazone was provided by Takeda Pharmaceutical (Osaka, Japan).

Generation of $Wfs1^{-/-}$ A^y/a mice To generate A^y/a mice lacking the $Wfs1$ gene, $Wfs1^{-/-}$ mice were bred with A^y/a mice to create the compound heterozygote ($Wfs1^{+/-}$ A^y/a). This heterozygote was bred with $Wfs1^{+/-}$ a/a , and $Wfs1^{-/-}$ A^y/a , $Wfs1^{+/+}$ A^y/a , $Wfs1^{-/-}$ a/a and $Wfs1^{+/+}$ a/a (wild-type [WT]) offspring were identified.

The $Wfs1$ genotype was determined by PCR. We used the sense primer 5'-CCCAGTTCTTGCTTTACCAC CAGG-3' and the anti-sense primers 5'-GCCTTCTTGAC GAGTTCTTCTGA-3' (derived from the neomycin resistance gene) and 5'-ACTTCGTCCAGCACTGGGGTCAG-3' (derived from the $Wfs1$ gene). A^y/a mice were identified by coat colour.

Physiological studies Body weights were measured weekly. Blood samples were collected from the tail vein. Non-fasting blood glucose was measured by the glucose oxidase method using a GlucoCard device (Arkray, Kyoto, Japan). Serum insulin levels were determined using an insulin ELISA kit (Morinaga Institute of Biological Science, Tokyo, Japan). Serum triacylglycerol was measured by high-performance liquid chromatography at Skylight Biotech (Akita, Japan), according to the procedure described by Usui et al. [33]. Intraperitoneal glucose tolerance test (ipGTT) and insulin tolerance test (ITT) were performed at 8 weeks of age.

Pancreatic insulin content Pancreases were removed and homogenised in acid/ethanol (0.7 mol/l HCl/ethanol 25:75 plus 0.1% Triton X-100 (vol./vol.)) and left at 4°C for 48 h, with sonication every 24 h. Homogenates were then centrifuged (3,000 g for 15 min) and the insulin content of the acid/ethanol supernatant fraction was measured using insulin ELISA. Protein in tissue extracts was determined using the BCA protein assay reagent.

Immunostaining and morphometry Formalin-fixed paraffin-embedded sections were de-paraffinised and re-hydrated, then incubated with primary antibodies. For immunofluorescent staining, appropriate FITC-conjugated or Cy3-conjugated anti-IgG was used. Detailed antibody information is given in the Electronic supplementary material (ESM). Immunohisto-

chemical analyses were performed, with at least three animals for each condition being killed for the purpose. For measurement of beta cell area, more than five pancreatic tissue sections per animal were randomly selected and stained with anti-insulin IgG/3,3'-diaminobenzidine tetrahydrochloride and haematoxylin. Microscopic photoimages were taken with a charge-coupled device (CCD) camera and the pancreatic and beta cell areas were each estimated using a computer program (Y. Uehara, S. Saeki and S. Saito S unpublished results).

Tissue preparation and electron microscopy All animals were anaesthetised with sodium pentobarbital (65 mg/kg, i.p.) and intracardially perfused with 2% glutaraldehyde (vol./vol.) and 4% paraformaldehyde (vol./vol.) in 0.1 mol/l phosphate buffer (pH 7.4) containing 0.2% picric acid (vol./vol.). Pancreatic sections (1 mm thick) were post-fixed with 1% OsO₄ (wt/vol.), block-stained with 2% uranyl acetate (wt/vol.), dehydrated, infiltrated with propylene oxide, placed in a mixture of propylene oxide and Epoxy resin (1:1), and flat-embedded on siliconised glass slides in Epoxy resin. Ultrathin sections were made and mounted on to copper grids. To enhance contrast, they were double stained with 2% uranyl acetate (wt/vol.) and 1% lead citrate (wt/vol.), and observed with a Hitachi H-7500 electron microscope (Hitachi High-Technologies, Tokyo, Japan) operating at 80 kV.

Mouse islet isolation and immunoblotting analysis Pancreatic islets were isolated as described previously [15]. For immunoblotting [34], approximately 100 islets from two to six mice were pooled, then immediately dissolved in lysis buffer containing 1% SDS (50 mmol/l Tris-HCl [pH 6.8], 1% SDS [wt/vol.], 10% glycerol [wt/vol.] and 50 mmol/l dithiothreitol). Anti-WFS1 (N-terminus) antibody has been described previously [15]. For information on other antibodies, see ESM.

Statistical analysis Results are expressed as means±SE. Differences between means were evaluated using ANOVA or Student's *t* test as appropriate. Differences were considered significant at $p < 0.05$.

Results

Characteristics of the mice Body weights were monitored weekly beginning at 4 weeks of age. A^y/a mice ($Wfs1^{+/+}$ A^y/a) were mildly, but significantly more obese than WT littermates ($Wfs1^{+/+}$ a/a) by 6 weeks of age (23.5±0.7 vs 21.5±0.5 g; $p < 0.05$). Similarly, $Wfs1^{-/-}$ A^y/a mice were also more obese than $Wfs1^{-/-}$ a/a mice by 6 weeks of age (23.9±0.3 vs 20.6±0.2 g; $p < 0.0001$). However, $Wfs1^{-/-}$ A^y/a mice had

lost their excess weight by 17 weeks of age (Fig. 1a). This is attributable to the development of overt diabetes due to severe insulin deficiency (Fig. 1b, c). In fact, non-fasted blood glucose levels of *Wfs1^{-/-} A^{y/a}* mice started to rise significantly from the age of 8 weeks, with all *Wfs1^{-/-} A^{y/a}* mice developing overt diabetes by 16 weeks of age (Fig. 1b). Ketosis manifested after age 16 weeks (data not shown). In contrast, blood glucose levels of *Wfs1^{+/+} A^{y/a}* and *Wfs1^{-/-} a/a* mice did not differ from those of WT mice. We also examined plasma insulin levels of these mice. At 12 weeks of age, the plasma insulin levels of *Wfs1^{+/+} A^{y/a}* mice were significantly higher than those of WT littermates, and *Wfs1^{-/-} a/a* and




Fig. 1 Weight, blood glucose and insulin levels of *Wfs1^{-/-} A^{y/a}* and other mice. **a** Weight of *Wfs1^{-/-} A^{y/a}* (triangles), *Wfs1^{+/+} A^{y/a}* (squares), *Wfs1^{-/-} a/a* (diamonds) and *Wfs1^{+/+} a/a* (WT, circles) mice over the course of 24 weeks. Values are the means±SE for $n=14-21$ mice. **b** Non-fasted blood glucose levels in *Wfs1^{-/-} A^{y/a}*, *Wfs1^{+/+} A^{y/a}*, *Wfs1^{-/-} a/a* and WT mice; key as above, $n=11-16$. $p<0.05$ for *Wfs1^{-/-} A^{y/a}* vs *Wfs1^{+/+} A^{y/a}*, *Wfs1^{-/-} a/a* and WT mice at 8 and 12 weeks; $p<0.001$ for *Wfs1^{-/-} A^{y/a}* vs *Wfs1^{+/+} A^{y/a}*, *Wfs1^{-/-} a/a* and WT mice at 16, 20 and 24 weeks. **c** Plasma immunoreactive insulin (IRI) levels in *Wfs1^{-/-} A^{y/a}* (white bars), *Wfs1^{+/+} A^{y/a}* (hatched bars), *Wfs1^{-/-} a/a* (grey bars) and WT (black bars) mice at 12 and 24 weeks of age. Data are presented as the means±SE for $n=7-13$ mice. *** $p<0.001$

Wfs1^{-/-} A^{y/a} mice. Interestingly, *Wfs1^{-/-} A^{y/a}* mice tended to be more hyperinsulinaemic than *Wfs1^{-/-} a/a* and WT at this age, although the differences did not reach statistical significance. However, at 24 weeks of age, plasma insulin levels in *Wfs1^{-/-} A^{y/a}* mice were markedly decreased (Fig. 1c).

Intraperitoneal glucose tolerance test and ITT were performed at 8 weeks (Fig. 2). *Wfs1^{+/+} A^{y/a}* mice, as well as *Wfs1^{-/-} A^{y/a}* mice, were already more insulin-resistant than *Wfs1^{+/+} a/a* and *Wfs1^{-/-} a/a* mice at this young age (Fig. 2a, d). There was no statistical difference in the ITT curve between *Wfs1^{+/+} A^{y/a}* and *Wfs1^{-/-} A^{y/a}* mice. Although glucose tolerance of *Wfs1^{+/+} A^{y/a}* mice was normal because of compensatory elevated insulin secretion (Fig. 2b, c), this compensation was not found in *Wfs1^{-/-} A^{y/a}* mice, whose glucose tolerance was impaired (Fig. 2e, f).

A similar, but milder phenotype was observed in the *Wfs1^{-/-} a/a* mice with high-fat diet-induced obesity (ESM Fig. 1). The high-fat diet caused obesity with hyperinsulinaemia in WT mice (*Wfs1^{+/+} a/a*). However, these mice were normoglycaemic (ESM Fig. 1a). In contrast, a high-fat diet induced hyperglycaemia in *Wfs1^{-/-} a/a* mice, although less prominently than in *Wfs1^{-/-} A^{y/a}* mice (mean non-fasting blood glucose 18.0 ± 2.7 mmol/l, $n=6$ vs 36.9 ± 2.4 mmol/l, $n=14$ at 24 weeks of age, $p<0.001$) (ESM Fig. 1b). Non-fasting insulin levels were lower, although not significantly, in high-fat diet-fed *Wfs1^{+/+} a/a* than in *Wfs1^{+/+} A^{y/a}* mice (402.9 ± 87.5 pmol/l, $n=9$ vs 605.7 ± 114.4 , $n=7$ at age 24 weeks, $p>0.05$) (ESM Fig. 1c).

Acceleration of selective beta cell apoptosis We immunohistochemically investigated the cause of insulin deficiency. In 24-week-old *Wfs1^{+/+} A^{y/a}* mice, islets were hypertrophic and larger (Fig. 3b, f, j) than in WT (Fig. 3a, e, i) and *Wfs1^{-/-} a/a* mice (Fig. 3c, g, k), reflecting responses to the increased insulin demand in *Wfs1^{+/+} A^{y/a}* mice. In the *Wfs1^{-/-} a/a* mice, insulin-positive beta cells were preserved (Fig. 3c, g) and there was no apparent difference from WT controls at this stage, except for a change in islet architecture (aberrant centric migration of alpha cells) (Fig. 3g, [15]). Interestingly and impressively, however, *Wfs1^{-/-} A^{y/a}* mice had small, irregularly shaped islets, in which insulin-positive beta cells were markedly decreased (Fig. 3d, h).

The results were confirmed by morphometric analysis showing that the insulin-positive area per pancreatic area in *Wfs1^{+/+} A^{y/a}* mice was increased as compared with that in WT and *Wfs1^{-/-} a/a* mice. In *Wfs1^{-/-} A^{y/a}* mice, the insulin-positive area was markedly reduced (Fig. 4a), as was the pancreatic insulin content (Fig. 4b).

Time courses of beta cell loss in *Wfs1^{-/-} A^{y/a}* islets are shown in Fig. 3m–o. In *Wfs1^{-/-} A^{y/a}* mice, insulin-positive beta cells were selectively and severely depleted by

Fig. 2 Insulin tolerance test and ipGTT. ITT (0.75 U/kg) (a, d) and ipGTT (2 g/kg) (b, c, e, f) were performed at 8 weeks of age on *Wfs1*^{+/+} *a/a* (WT) (white circles), *Wfs1*^{+/+} *A*^y/*a* (white squares), *Wfs1*^{-/-} *a/a* (black circles) and *Wfs1*^{-/-} *A*^y/*a* (black squares). Values are means±SEM, *n*=3–10 per group (ITT) and *n*=7–10 per group (ipGTT). **p*<0.05, ***p*<0.01 compared with the corresponding *a/a* mice





Fig. 3 Selective beta cell loss in islets of *Wfs1*^{-/-} *A*^y/*a* mice. a–l Pancreatic sections from 24-week-old *Wfs1*^{+/+} *a/a* (WT), *Wfs1*^{+/+} *A*^y/*a*, *Wfs1*^{-/-} *a/a* and *Wfs1*^{-/-} *A*^y/*a* mice were immunostained for insulin (brown) (a–d), scale bar 100 nm. e–h Immunofluorescence staining for insulin (green), glucagon (red) and (i–l) somatostatin (red). m–o Representative time course of beta cell loss in islets from *Wfs1*^{-/-} *A*^y/*a* mice. Insulin (green) and glucagon (red) were immunostained. At 8 weeks (m), most islets were indistinguishable from those of WT mice. By the 16th week (n), normal islet architecture had been destroyed and beta cell numbers were apparently decreased. By week 24 (o), few beta cells remained. p–s Immunohistochemistry results for pro-apoptotic active caspase-3 in pancreatic sections from WT (p), *Wfs1*^{+/+} *A*^y/*a* (q), *Wfs1*^{-/-} *a/a* (r) and *Wfs1*^{-/-} *A*^y/*a* mice (s). Activated caspase-3 staining was performed at age 16 weeks. Positive cells were found in *Wfs1*^{-/-} *A*^y/*a* islets (s), but not in islets from other mice. Scale bar, 50 nm






Fig. 4 Insulin-positive areas and insulin content of pancreases. **a** Ratios of total insulin-positive area to the entire pancreatic area were estimated for $Wfs1^{+/+} a/a$ (WT, black bars), $Wfs1^{+/+} A^y/a$ (hatched bars), $Wfs1^{-/-} a/a$ (grey bars) and the $Wfs1^{-/-} A^y/a$ (white bars) mice at age 24 weeks. At least five sections from each mouse were prepared and examined. Data are means \pm SE from four animals for each group. *** p <0.001. **b** Insulin contents extracted from whole pancreases of WT, $Wfs1^{+/+} A^y/a$, $Wfs1^{-/-} a/a$ and $Wfs1^{-/-} A^y/a$ mice (key as above) at age 24 weeks (means \pm SE, n =7). *** p <0.001

24 weeks of age, whereas glucagon-positive alpha cells and somatostatin-positive delta cells were preserved (Fig. 3h, l). This selective beta cell loss was due to apoptotic cell death as indicated by caspase-3 activation in islets of 16-week-old mice (Fig. 3p–s).


Ultrastructural analysis We performed ultrastructural analyses of pancreatic beta cells from 12-week-old mice using electron microscopy. The beta cells were distinguished from alpha and delta cells by the appearance of their secretory granules. The beta cell granules had a white halo, not evident in alpha and delta cell granules.

In A^y/a mice pancreatic beta cells, rough ER was well developed and structurally indistinguishable from that of WT mice (Fig. 5a, b, e, f). In $Wfs1^{-/-} a/a$ mice, ER was

dilated and beta cell secretory granules were electron-lucent in some pancreatic beta cells (Fig. 5c, g). In contrast, in $Wfs1^{-/-} A^y/a$ mice, ER was severely dilated in almost all pancreatic beta cells and secretory granules were reduced in size and electron density (Fig. 5d, h). In addition, mitochondrial swelling was observed in these beta cells. ER abnormality appears to be a common finding in rodent models of ER stress-related beta cell failure [26, 29, 30]. Riggs et al. reported similar findings in their beta cell-specific $Wfs1$ knockout mouse [22]. Changes were milder in their mice than in our $Wfs1^{-/-} A^y/a$ mice and no mitochondrial abnormalities were mentioned. The difference may represent different stages of the same process.

Unfolded protein response in pancreatic islets of obese and $Wfs1^{-/-}$ mice Our group and others have shown that $Wfs1^{-/-}$ beta cells are susceptible to ER stress and that WFS1 deficiency itself evokes the UPR [15, 20, 22]. If insulin resistance induces ER stress in pancreatic beta cells via increased demand for insulin biosynthesis and secretion, beta cell death would presumably be accelerated in $Wfs1^{-/-}$ mice that become insulin-resistant. To examine this possibility, we first analysed WFS1 protein levels and the UPR in beta cells under insulin-resistant conditions. Western blot analysis at 12 weeks, when some mice were already hyperglycaemic, but more than half remained essentially normoglycaemic (Fig. 1b), revealed WFS1 protein levels to be increased in obese $Wfs1^{+/+} A^y/a$ murine islets as compared with those in $Wfs1^{+/+} a/a$ (WT) mice (Fig. 6a). Levels of ER chaperones 94 kDa glucose-regulated protein (GRP94) and 78 kDa glucose-regulated protein (GRP78) were also apparently increased in $Wfs1^{+/+} A^y/a$ and $Wfs1^{-/-} a/a$ mice as compared

Fig. 5 Electron micrograph of pancreatic beta cells. Ultrastructural analysis using electron microscopy was performed on islets from $Wfs1^{+/+} a/a$ (WT) (a, e), $Wfs1^{+/+} A^y/a$ (b, f), $Wfs1^{-/-} a/a$ (c, g) and $Wfs1^{-/-} A^y/a$ mice (d, h) at age 12 weeks. Magnification was as shown, i.e. lower (a–d) and higher (e–h). M, mitochondrion; N, nucleus; SG, secretory granule; V, blood vessel






Fig. 6 Unfolded protein responses of pancreatic islets. **a** Isolated murine islets were subjected to SDS/PAGE and blotted using antibodies directed against WFS1 (N-terminus), C-terminal lys-asp-glu-leu (GRP94, GRP78), eIF2 α , phosphorylated eIF2 α (p-eIF2 α) and glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Lane 1, $Wfs^{+/+} a/a$ (WT); lane 2, $Wfs^{+/+} A/a$; lane 3, $Wfs^{-/-} a/a$; lane 4, $Wfs^{-/-} A/a$. The blot is representative of experiments repeated three times. **b–f** Summary of respective protein/

GAPDH levels from three independent experiments. Data (means \pm SE) are expressed relative to those of the $Wfs^{+/+} a/a$ (WT) islet preparation. Although the differences did not reach statistical significance, the UPR tended to be enhanced in $Wfs^{+/+} A/a$ (hatched bars) and $Wfs^{-/-} a/a$ (grey bars) mice as compared with the WT ($Wfs^{+/+} a/a$) (black bars) mice, and appeared to be further enhanced in $Wfs^{-/-} A/a$ (white bars) mice. Experiments were performed using 12-week-old mice

with WT mice (Fig. 6a–c). Therefore, ER stress had been triggered in A/a and $Wfs^{-/-}$ mice. In $Wfs^{-/-} A/a$ mice, levels of these ER chaperones appeared to be further increased (Fig. 6a–c). Phosphorylation of the translation initiation factor-2, subunit α (eIF2 α) attenuates protein translation under ER stress conditions. Similar changes were observed in total eIF2 α protein and phosphorylated eIF2 α amounts in the islets of $Wfs^{+/+} A/a$, $Wfs^{-/-} a/a$ and $Wfs^{-/-} A/a$ mice (Fig. 6a, d–f). We also measured *Grp78* (also known as *Hspa5*), *Grp94* (also known as *Hsp90b1*) and spliced *Xbp1* mRNA expression in 8-week-old mice islets. A similar trend was observed, although changes were less prominent at this age (ESM Fig. 2). These data suggest that A/a murine islets are exposed to ER stress and that increased ER stress is among the likely causes of rapid and prominent beta cell apoptosis in $Wfs^{-/-} A/a$ murine islets.

Pioglitazone prevented beta cell loss and diabetes in $Wfs^{-/-} A/a$ mice Our observations suggest that beta cell overload markedly accelerates beta cell death and diabetes development in $Wfs^{-/-} a/a$ mice. Therefore, we attempted to reduce this beta cell overload, which is likely to be due to obesity-associated insulin resistance, with pioglitazone

treatment. Mice were allowed free access to normal chow containing 0.01% pioglitazone immediately after weaning (4 weeks of age). The average dose of pioglitazone was estimated to be 15 mg kg⁻¹ day⁻¹.

Pioglitazone ameliorated insulin resistance as assessed by the non-fasting insulin levels in $Wfs^{+/+} A/a$ mice (mean non-fasting insulin without pioglitazone 513.5 \pm 49.9 pmol/l, $n=13$ vs with pioglitazone 326.9 \pm 61.0 pmol/l, $n=7$, $p<0.05$) at 12 weeks of age. Serum triacylglycerol levels were also markedly improved (Fig. 7). The $Wfs^{-/-} A/a$ mice gained more weight with pioglitazone treatment. As early as 7 weeks of age, $Wfs^{-/-} A/a$ mice treated with pioglitazone were heavier (28.7 \pm 0.7 g, $n=11$) than $Wfs^{+/+} A/a$ (25.5 \pm 0.7 g, $n=15$, $p<0.01$) and $Wfs^{-/-} a/a$ (26.0 \pm 0.4 g, $n=20$, $p<0.01$) mice fed normal chow (Fig. 8a). Despite the increased body weight, pioglitazone prevented diabetes development. Average non-fasted blood glucose levels were significantly lower in pioglitazone-treated $Wfs^{-/-} A/a$ mice than in untreated $Wfs^{-/-} A/a$ mice (12.9 \pm 0.9 vs 20.5 \pm 1.9 mmol/l, $p<0.002$) at 16 weeks (Fig. 8b). Histological analyses revealed pancreatic beta cells to be very well preserved in pioglitazone-treated $Wfs^{-/-} A/a$ mice (Fig. 8c–f).




Fig. 7 Serum triacylglycerol (TG) levels with/without pioglitazone. Serum triacylglycerol levels were measured in 12-week-old mice. After weaning (4 weeks of age), the mice were fed standard mouse chow with/without 0.01% pioglitazone. Values are means±SE from three to five mice. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$

Pioglitazone did not suppress the UPR To investigate whether pioglitazone treatment reduces ER stress in pancreatic beta cells, we examined UPR activation by Western blot analysis using isolated murine islets. Interestingly and unexpectedly, pioglitazone did not reduce either ER chaperones or eIF2 α levels/phosphorylation in *Wfs1*^{-/-} *a/a* and *Wfs1*^{-/-} *A^y/a* mice (Fig. 9a, ESM Fig. 3). Similar results were obtained for spliced *Xbp1*, *Grp78*, *Grp94* and *Chop* (also known as *Ddit3*) mRNA expression in 8-week-old mice islets (ESM Fig. 2).

Electron microscopic examination revealed markedly improved ER appearance in *Wfs1*^{-/-} *A^y/a* pancreatic beta cells after pioglitazone treatment (Fig. 9b–e, see also Fig. 5). Without the treatment, almost all beta cells had markedly distended ER (Fig. 9b, c). However, after the treatment, the ER distension was markedly reduced and some beta cells appeared to be normal (Fig. 9d, e), although heterogeneity was observed among the cells.

Discussion

Here we demonstrated that *Wfs1*^{-/-} *A^y/a* mice on a C57BL/6J background develop early-onset insulin-deficient diabetes mellitus as early as 6 weeks of age and that most are overtly diabetic by the 16th week, whereas neither *Wfs1*-deficient *Wfs1*^{-/-} *a/a* nor obese agouti yellow (*Wfs1*^{+/+} *A^y/a*) mice had developed overt diabetes by the 24th week. In *Wfs1*^{-/-} *A^y/a* murine islets, beta cell mass was dramatically decreased due to increased beta cell apoptosis. WFS1 protein clearly plays a pivotal role in beta cell survival.

Our previous study had demonstrated that approximately half of *Wfs1*^{-/-} mice develop diabetes when they have the hybrid genetic background of C57BL/6J and 129Sv, while, unexpectedly with the C57BL/6J background, there is no apparent increase in blood glucose levels even at 36 weeks [15]. Because beta cells of *Wfs1*^{-/-} mice were also shown to be susceptible to ER stress in ex-vivo experiments and cultured cells [15, 21], we sought to test this in the in vivo model.




Fig. 8 Pioglitazone prevents diabetes and beta cell loss. The standard mouse chow with 0.01% pioglitazone was started at 4 and continued until 24 weeks of age in *Wfs1*^{-/-} *A^y/a* mice. **a** Graph showing body weight changes (means±SE, $n = 11–20$) and **(b)** non-fasted blood glucose levels ($n = 11–16$). Black circles, *Wfs1*^{-/-} *A^y/a* mice without treatment; squares, *Wfs1*^{-/-} *A^y/a* mice with pioglitazone treatment; white circles, control *Wfs1*^{+/+} *A^y/a* mice. **c** Insulin (green) and glucagon (red) were stained in pancreatic sections from *Wfs1*^{-/-} *A^y/a* mice and **(d)** from pioglitazone-treated *Wfs1*^{-/-} *A^y/a* mice at 24 weeks of age. **e** Insulin (brown) was stained in pancreatic sections from *Wfs1*^{-/-} *A^y/a* mice and **(f)** from pioglitazone-treated *Wfs1*^{-/-} *A^y/a* mice at 24 weeks of age




Fig. 9 Unfolded protein responses and ultrastructural changes in beta cells after pioglitazone treatment. **a** *Wfs1*^{-/-} *a/a* (lanes 1, 3) and *Wfs1*^{-/-} *A^{y/a}* (lanes 2, 4) mice were fed standard mouse chow with/without 0.01% pioglitazone after weaning (4 weeks of age). Isolated murine islets at 12 weeks of age were subjected to SDS/PAGE and blotted using antibodies directed against WFS1 (N-terminus), C-terminal lys-asp-glu-leu (GRP94, GRP78), eIF2 α , phosphorylated eIF2 α (p-eIF2 α) and glyceraldehyde 3-phosphate dehydrogenase (GAPDH). The blot is representative of three independent experiments. Densitometric quantification of these results is presented in ESM Fig. 3). Electron micrographs of islets from *Wfs1*^{-/-} *A^{y/a}* mice (12-week-old) without (**b**, **c**) or with (**d**, **e**) pioglitazone treatment. Arrows, ER; N, nucleus

The *A^{y/a}* mouse is a genetic model of mild obesity/insulin resistance with compensatory beta cell hyperplasia [31] (Figs 1 and 3). Increased demand for insulin biosynthesis and secretion has been thought to cause ER stress in pancreatic beta cells, and here, in fact, we demonstrated, in *A^{y/a}* murine islets, that ER chaperone expression was apparently increased at 12 weeks of age (Fig. 6). Similar results have been demonstrated in another insulin-resistant mouse model [7]. In addition, WFS1 protein levels were also increased (Fig. 6a). Our group

and others have shown WFS1 protein levels to be upregulated by ER stress [19, 20, 35]. These data suggest that increased insulin demand under insulin-resistant conditions produces chronic ER stress in beta cells. In addition, NEFA, which are elevated in these insulin-resistant models, may also contribute to the activation of UPR [32]. In this regard, Lipson et al. recently demonstrated that hyperglycaemia activates inositol-requiring protein-1 (IRE1) α , an ER-resident transmembrane protein kinase regulating UPR in beta cells. Although IRE1 α activation by transient hyperglycaemia is beneficial to beta cells, chronically sustained hyperglycaemia causes ER stress and suppresses insulin gene expression [36]. Glucose regulation of the UPR has also been reported [37].

Dramatically decreased beta cell numbers in *Wfs1*^{-/-} *A^{y/a}* mice suggest that increased insulin demand triggers pancreatic beta cell apoptosis in *Wfs1*-deficient mice. ER stress induces WFS1 protein production and lack of this protein itself enhances the UPR [15, 19–21]. This was true in our mice (Fig. 6), with the UPR apparently further enhanced in mildly obese *Wfs1*^{-/-} *A^{y/a}* mice. These data support the hypothesis that beta cell loss in Wolfram syndrome is, at least partly, caused by increased ER stress in beta cells. Although the precise function of ER-resident WFS1 protein remains unknown, our overall results suggest that this protein is likely to protect beta cells from ER stress-induced apoptosis and that Wolfram syndrome is an ER stress-related disease.

In patients with type 2 diabetes, very gradual, but progressive beta cell loss is caused by many factors, both genetic and acquired. One well-established mechanism of acquired beta cell loss is oxidative stress, which appears to be a major mediator of glucotoxicity [38]. We observed 4-hydroxy-2-nonenal-modified protein, an oxidative stress marker, in *Wfs1*^{-/-} *A^{y/a}* murine islets at age 16 weeks (data not shown), suggesting that oxidative stress is also involved in beta cell apoptosis. Oxidative stress is likely to have been secondary to chronic hyperglycaemia because most *Wfs1*^{-/-} *A^{y/a}* mice had developed hyperglycaemia by this age (Fig. 1b). In *Wfs1*^{-/-} *A^{y/a}* mice, the vicious cycle associated with ER stress and oxidative stress probably exacerbates beta cell apoptosis. In this regard, it is again worth emphasising that insulin resistance induces ER stress in pancreatic beta cells [7]. Currently, we do not know the full extent of ER stress involvement in beta cell failure in human type 2 diabetes. However, it is possible that this vicious cycle associated with ER stress and oxidative stress plays an important role in beta cell deterioration [39].

Pioglitazone treatment almost completely prevented the development of diabetes and beta cell loss in *Wfs1*^{-/-} *A^{y/a}* mice. One simple explanation is that insulin resistance was ameliorated by pioglitazone treatment, reducing ER stress in pancreatic beta cells and preventing beta cell death.